Phibro Animal Health Corp.

How big is Phibro Animal Health Corp.?

As of Jun 24, Phibro Animal Health Corp. has a market capitalization of 991.05 million, with net sales of 1,190.67 million and a net profit of 31.79 million over the latest four quarters. Shareholder's funds are 256.64 million, and total assets amount to 982.18 million.

As of Jun 18, Phibro Animal Health Corp. has a market capitalization of 991.05 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 24, the company reported net sales of 1,190.67 million and a net profit of 31.79 million for the latest four quarters.<BR><BR>As of Jun 24, the shareholder's funds were 256.64 million, and total assets amounted to 982.18 million.

What does Phibro Animal Health Corp. do?

Phibro Animal Health Corp. is a global company specializing in animal health and mineral nutrition, with recent net sales of $348 million and a market cap of approximately $991 million. Key financial metrics include a P/E ratio of 21.00 and a dividend yield of 1.96%.

Overview:<BR>Phibro Animal Health Corp. is a global diversified animal health and mineral nutrition company operating in the Pharmaceuticals & Biotechnology industry with a market cap in the micro-cap bracket.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 348 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 21 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 991.05 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00 <BR>Dividend Yield: 1.96% <BR>Debt Equity: 2.50 <BR>Return on Equity: 17.19% <BR>Price to Book: 3.73<BR><BR>Contact Details:<BR>Address: 300 Frank W Burr Blvd Ste 21 Fl 3, TEANECK NJ: 07666 <BR>Tel: 1 201 3297300 <BR>Fax: 1 302 6555049 <BR>Website: https://www.pahc.com/

Should I buy, sell or hold Phibro Animal Health Corp.?

Who are in the management team of Phibro Animal Health Corp.?

As of March 2022, the management team of Phibro Animal Health Corp. includes Chairman and CEO Jack Bendheim, along with Jonathan Bendheim, Daniel Bendheim, and several independent directors. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Phibro Animal Health Corp. includes the following individuals:<BR><BR>- Mr. Jack Bendheim: Chairman of the Board, President, Chief Executive Officer, Director<BR>- Mr. Jonathan Bendheim: Director and President, MACIE Region and General Manager of Israel Operations<BR>- Mr. Daniel Bendheim: Executive Vice President, Corporate Strategy and Director<BR>- Mr. Gerald Carlson: Independent Director<BR>- Mr. E. Thomas Corcoran: Independent Director<BR>- Mr. Sam Gejdenson: Independent Director<BR>- Ms. Mary Malanoski: Independent Director<BR>- Ms. Carol Wrenn: Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Phibro Animal Health Corp. technically bullish or bearish?

As of August 7, 2025, Phibro Animal Health Corp. shows a strong bullish trend supported by positive MACD, Bollinger Bands, and moving averages, with a year-to-date return of 93.05% compared to the S&P 500's 12.22%.

As of 7 August 2025, the technical trend for Phibro Animal Health Corp. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend in both periods. Daily moving averages are bullish, while the KST shows bullish momentum on both weekly and monthly charts. However, the OBV is mildly bullish weekly but mildly bearish monthly, suggesting some divergence in volume trends.<BR><BR>In terms of performance, Phibro has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 93.05% compared to the S&P 500's 12.22%, and a one-year return of 83.02% versus 17.14%. Overall, the technical indicators point to a strong bullish stance for the stock.

Is Phibro Animal Health Corp. overvalued or undervalued?

As of October 17, 2025, Phibro Animal Health Corp. is considered attractively valued with a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, outperforming peers and achieving a year-to-date return of 89.14%.

As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, which suggests that the stock is reasonably priced relative to its growth potential.<BR><BR>When compared to peers, Phibro Animal Health Corp. has a P/E of 29.58, which is significantly higher than the negative P/E ratios of its risky counterparts like Soleno Therapeutics, Inc. and Arcutis Biotherapeutics, Inc. Additionally, the company has demonstrated strong returns, with a year-to-date return of 89.14% compared to the S&P 500's 13.30%, reinforcing the attractiveness of its valuation.